Quick-Med Technologies' CEO Talks With The Wall Street Transcript - In-depth Interview Discusses Company Strategy

    GAINESVILLE, FL, December 17, 2009 /24-7PressRelease/ -- Quick-Med Technologies, Inc. (OTCBB: QMDT) announced today that The Wall Street Transcript (TWST) has included an interview with the Company's CEO, J. Ladd Greeno, in the publication's latest Pharmaceutical Report.

This in-depth interview explores the progress that Quick-Med has made with its NIMBUS antimicrobial technology after FDA clearance in 2009. It also discusses the market opportunities that the Company is pursuing with each of its four platform technologies: NIMBUS antimicrobials, NimbuDerm hand sanitizer and hard surface disinfectant, Stay Fresh textile treatment, and MultiStat skin anti-aging and MMP inhibitor technology. In responding to the interviewer's questions, Mr. Greeno overviews Quick-Med's strategy, the Company' technologies, and target markets.

The entire 2,900 word interview is available on the Downloads page of the Company's website: http://www.quickmedtech.com/download-documents.php The Wall Street Transcript does not endorse the views of any interviewee nor does it make stock recommendations.

The Wall Street Transcript's Pharmaceuticals Report offers a timely review of the sector to serious investors and industry executives. This 76-page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers.

About The Wall Street Transcript

For more than 40 years, The Wall Street Transcript has been interviewing CEOs of Public Companies, Industry Analysts, and Money Managers. It is a subscriber-based online and print publication for institutional investors and is available directly in print, at TWST.com, on institutional/corporate intranets and indirectly via major databases, including First Call, Lexis-Nexis, Factiva, and Dialog. For more information, see www.TWST.com.

About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the healthcare and consumer markets. Quick-Med is developing NIMBUS and NimbuDerm applications in several advanced medical device formats including traditional and advanced wound care dressings, adhesives, medical grade thermoplastics, and skin sanitizers. NIMBUS is the FDA-cleared technology that is being marketed in a line of wound dressings. The company has also recently announced its Stay Fresh technology for apparel and other textile applications. For more information, see: www.quickmedtech.com.

CONTACT:
J. Ladd Greeno, CEO
Tel. (888) 835.2211 Ext 102
Email: [email protected]

2009 Quick-Med Technologies, Inc. All rights reserved. NIMBUS and MultiStat are registered trademarks and NimbuDerm and Stay Fresh are trademarks of Quick-Med Technologies, Inc.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.

# # #